IPO registrations (S-1, F-1) · Registrants
EoCene Ltd.
- SEC CIK
- 1595353 · filings on EDGAR ↗
- Name on the registration
- Galmed Pharmaceuticals Ltd.
- Former names
- Galmed Pharmaceuticals Ltd. (2013–2026)
- Registration
- Form F-1, first filed 2014-02-06, last 2025-08-18; 5 initial registrations, 5 amendments
- Outcome
- Final prospectus filed 2014-03-13; declared effective 2014-03-12
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- L3
- Business address
- C/O MEITAR LAW OFFICES, 16 ABBA HILLEL SILVER RD., Ramat Gan
- EIN
- 98-1147233
- Ticker
- EOCN (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- EoCene Ltd. on the corporate pages
Offering terms
- Proposed price range
- $12.00–$14.00 per share (F-1/A filed 2014-03-11)
- Final price
- $13.50 per share, within the range (424B4 filed 2014-03-13, an initial public offering)
- Shares sold
- 2,837,400
- Gross proceeds
- $38,304,900 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol GLMD
- Lead underwriters
- Maxim Group (2,482,725 shares)
- Syndicate
- MLV & Co (212,805); Feltl and Company (141,870)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Galmed Pharmaceuticals Ltd. EXACT (CIK (EXACT))
- SEC filer: Galmed Pharmaceuticals Ltd. EXACT (CIK (EXACT))
Filings 28
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-02-06 | F-1 | F-1 (foreign registration) | Galmed Pharmaceuticals Ltd. | 0001144204-14-006610 ↗ |
| 2014-02-28 | F-1/A | F-1/A (amendment) | Galmed Pharmaceuticals Ltd. | 0001144204-14-012612 ↗ |
| 2014-03-11 | F-1/A | F-1/A (amendment) | Galmed Pharmaceuticals Ltd. | 0001144204-14-014712 ↗ |
| 2014-03-12 | F-1MEF | F-1MEF (added securities) | Galmed Pharmaceuticals Ltd. | 0001144204-14-015291 ↗ |
| 2014-03-12 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-14-000644 ↗ |
| 2014-03-13 | 424B4 | 424B4 (final prospectus) | Galmed Pharmaceuticals Ltd. | 0001144204-14-015358 ↗ |
| 2015-07-01 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-15-001788 ↗ |
| 2018-04-02 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-18-000736 ↗ |
| 2021-04-01 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-21-001260 ↗ |
| 2023-06-16 | F-1 | F-1 (foreign registration) | Galmed Pharmaceuticals Ltd. | 0001493152-23-021672 ↗ |
| 2023-06-28 | F-1/A | F-1/A (amendment) | Galmed Pharmaceuticals Ltd. | 0001493152-23-022693 ↗ |
| 2023-07-12 | F-1/A | F-1/A (amendment) | Galmed Pharmaceuticals Ltd. | 0001493152-23-024354 ↗ |
| 2023-07-13 | F-1/A | F-1/A (amendment) | Galmed Pharmaceuticals Ltd. | 0001493152-23-024507 ↗ |
| 2023-07-14 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-23-002093 ↗ |
| 2023-07-18 | 424B4 | 424B4 (final prospectus) | Galmed Pharmaceuticals Ltd. | 0001493152-23-024789 ↗ |
| 2023-11-29 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-23-003480 ↗ |
| 2024-08-30 | F-1 | F-1 (foreign registration) | Galmed Pharmaceuticals Ltd. | 0001493152-24-034598 ↗ |
| 2024-09-09 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-24-002767 ↗ |
| 2024-10-21 | F-1 | F-1 (foreign registration) | Galmed Pharmaceuticals Ltd. | 0001493152-24-041776 ↗ |
| 2024-10-28 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-24-003299 ↗ |
| 2024-11-21 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-24-003548 ↗ |
| 2025-04-08 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-25-001032 ↗ |
| 2025-08-18 | F-1 | F-1 (foreign registration) | Galmed Pharmaceuticals Ltd. | 0001641172-25-024659 ↗ |
| 2025-08-21 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-25-002710 ↗ |
| 2025-09-02 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-25-002797 ↗ |
| 2025-09-02 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-25-002804 ↗ |
| 2026-04-01 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-26-001038 ↗ |
| 2026-09-03 | EFFECT | EFFECT (declared effective) | Galmed Pharmaceuticals Ltd. | 9999999995-26-002874 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-11 | F-1/A | registration statement | $12.00–$14.00 | 2,350,000 | - | Nasdaq GLMD | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2014-03-13 | 424B4 | final prospectus | $13.50 | 2,837,400 | $38,304,900 | Nasdaq GLMD | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Baharaff Allen | Director,Officer | Chief Executive Officer | 1 | 2026 | |
| Brosgart Carol L | Director | 1 | 2026 | ||
| Cohen Doron Leib | Officer | Chief Financial Officer | 1 | 2026 | |
| Nehemya Guy | Officer | Chief Operating Officer | 1 | 2026 | |
| Nir Shmuel | Director | 1 | 2026 | ||
| Nissimov Brueck Liat | Officer | Chief Scientific Officer | 1 | 2026 | |
| Poshinski Amir | Director | 1 | 2026 | ||
| SIDRANSKY DAVID | Director | 1 | 2026 | ||
| Stenzler Yohai | Officer | Chief Accounting Officer | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2017-08-15 | Galmed Pharmaceuticals Ltd. | Pharmaceuticals | $350,000 | $100,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Galmed Pharmaceuticals Ltd. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Galmed Pharmaceuticals Ltd. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.